Search

everythinglearnresearchcommunity

for

Search:↓

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

The conversation discusses the link between seborrheic dermatitis, acne, and male pattern baldness, suggesting that DHT may cause both skin conditions and hair loss. Treatments mentioned include RU58841, finasteride, dutasteride, minoxidil, Nizoral shampoo, and other topical anti-androgens.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

. CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.